遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場レポート：動向、予測、競合分析 (2031年まで)

世界の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場は、女性用市場と男性用市場に機会があり、将来性が有望視されます。世界の遺伝子組み換えヒト卵胞刺激ホルモン (FSH) 注射剤市場は、2025年から2031年にかけてCAGR 5.3％で成長すると予想されています。この市場の主な促進要因は、不妊症の有病率の増加とバイオシミラーの利用可能性の拡大です。

• Lucintel社の予測では、種類別では150IUが予測期間中に最も高い成長を遂げる見込みです。
• 用途別では、女性用が高い成長を遂げると予想されます。
• 地域別では、アジア太平洋が予測期間中に最も高い成長が見込まれます。

遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場の新たな動向

遺伝子組み換えヒト卵胞刺激ホルモン注射剤業界は、医療行為の変化、技術のアップグレード、患者の要求によって劇的な変化を遂げています。いくつかの顕著な動向は、その将来のコースを定義しています。

• 個別化された不妊治療：臨床医は、FSH投与量と治療期間を最適化することにより、副作用を減らしながら成功率を最大化するために、診断と病歴を用いて不妊治療プロトコルを個別化する傾向を強めています。
• 遺伝子組み換えFSHへの移行：遺伝子組み換えFSHは、その純度、一貫性、安全性から、尿ベースの製品よりも人気が高まっています。一貫した性能により、臨床医と患者の受容性が高まり、市場シェアが拡大しました。
• バイオシミラーの出現：オリジナルのFSHの特許が切れるにつれ、バイオシミラー製品が登場しています。バイオシミラー製品は、有効性と安全性が同等でありながら低価格であるため、治療へのアクセスが拡大し、価格競争が促進されています。
• ドラッグデリバリーの向上：プレフィルドペンや長時間作用型FSH製剤などの技術は利便性を高め、注射の痛みを最小限に抑え、患者の治療へのアドヒアランスを向上させます。
• 治療用途の拡大：不妊症以外の内分泌・生殖系疾患に対する遺伝子組み換えFSHの研究が進められており、臨床応用と市場機会が拡大する可能性があります。

これらの動向は、技術革新を促進し、治療へのアクセスを向上させ、これらの救命治療の幅広い用途を開拓することで、遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場を再定義するものです。個別化治療、最先端の製剤、手頃な価格の選択肢の重視は、今後も市場動向を定義し続けると思われます。

遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場の最近の動向

遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場は、有効性、安全性、患者の利便性を高めるための絶え間ない技術革新によって支配されています。このような開発は、ドラッグの製剤化からデリバリー、治療用途に至るまで、さまざまな次元に及んでいます。

• 新規製剤：製薬会社は、遺伝子組み換えFSHのより優れた製剤を開発するための技術革新を続けています。これには、注射の回数を減らす徐放性製剤や、起こりうる副作用を防ぐために賦形剤の含有量を減らしたより安定な製剤の開発が含まれます。例えば、ある企業は、より生理的なホルモン放出パターンを長時間にわたって持続させる徐放性製剤を研究しており、その結果、治療成績が改善されるであろう。
• バイオシミラーの利用可能性の拡大：先駆的な遺伝子組み換え型FSH製剤の多くが特許満了を迎え、バイオシミラー製剤がさまざまな市場で入手しやすくなっています。バイオシミラーは、それぞれの参照製品と比較して同様の有効性と安全性を証明するために広範に試験され、患者に手頃な治療を提供しています。バイオシミラーの出現は市場競争を促進し、価格を下げ、必要な不妊治療へのアクセスを向上させることができます。
• 製造工程の改善：組み換えDNA技術と細胞培養プロセスの継続的な改善により、組み換えFSHのより費用対効果の高い効率的な製造プロセスがもたらされています。このような製造工程の改善により、世界的な需要の増加に対応する高品質な製品を安定的かつ安定的に供給することができます。製造工程が改善されれば、治療費全体を下げることができ、より多くの患者が治療を受けられるようになります。
• 患者の利便性向上の重視：ドラッグデリバリーシステムは、患者の利便性を高めるために変化しています。使いやすいデザイン、細い針、正確な投与機構を備えたプレフィルドペンの人気が高まっています。これらの特徴は、自己投与を容易にし、注射に伴う不安を最小限に抑え、治療レジメンのコンプライアンスを向上させます。患者にとっての利便性を重視することで、不妊治療を受ける患者の負担を軽減し、利便性を高めることを目的としています。
• 新規治療用途の検討：主に生殖補助医療に応用されていますが、他の疾患の治療への組み換え型FSHの可能性も検討されています。これには、ある種のホルモン欠乏症のコントロールや不妊症以外の生殖の健康への利用を試験することが含まれます。これらの用途がまだ検討中であるとしても、肯定的な結果が得られれば、組み換えFSHの治療への応用が大きく広がる可能性があります。

これらの大きな進歩は、治療方法を進歩させ、患者へのアクセスを容易にし、これらの重要な薬剤の臨床用途を広げる可能性があることによって、遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場に累積的に影響を与えています。製剤、製造、送達、治療使用における技術革新が引き続き重視されていることは、ダイナミックに変化する市場環境を反映しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

• 背景と分類
• サプライチェーン

第3章 市場動向と予測分析

• マクロ経済の動向と予測
• 業界の促進要因と課題
• PESTLE分析
• 特許分析
• 規制環境

第4章 世界の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場：種類別

• 概要
• 魅力分析：種類別
• 75IU：動向と予測（2019～2031年）
• 150IU：動向と予測（2019～2031年）
• 300IU：動向と予測（2019～2031年）
• その他：動向と予測（2019～2031年）

第4章 世界の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場：用途別

• 概要
• 魅力分析：用途別
• 女性用：動向と予測（2019～2031年）
• 男性用：動向と予測（2019～2031年）

第6章 地域分析

• 概要
• 世界の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場：地域別

第7章 北米の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場

• 概要
• 北米の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場：種類別
• 北米の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場：用途別
• 米国の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場
• メキシコの遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場
• カナダの遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場

第8章 欧州の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場

• 概要
• 欧州の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場：種類別
• 欧州の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場：用途別
• ドイツの遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場
• フランスの遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場
• スペインの遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場
• イタリアの遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場
• 英国の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場

第9章 アジア太平洋の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場

• 概要
• アジア太平洋の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場：種類別
• アジア太平洋の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場：用途別
• 日本の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場
• インドの遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場
• 中国の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場
• 韓国の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場
• インドネシアの遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場

第10章 その他の地域 (ROW) の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場

• 概要
• その他の地域 (ROW) の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場：種類別
• その他の地域 (ROW) の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場：用途別
• 中東の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場
• 南米の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場
• アフリカの遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場

第11章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析
  • 競争企業間の敵対関係
  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
• 市場シェア分析

第12章 機会と戦略分析

• バリューチェーン分析
• 成長機会分析
  • 成長機会：種類別
  • 成長機会：用途別
• 世界の遺伝子組み換えヒト卵胞刺激ホルモン注射剤市場の新たな動向
• 戦略分析
  • 新製品開発
  • 認証・ライセンシング
  • 企業合併・買収 (M&A) 、契約、提携、合弁事業

第13章 バリューチェーン上の主要企業のプロファイル

• 競合分析
• Merck
• Organon
• Gedeon Richter
• Ferring
• Changchun High-Tech

第14章 付録

• 図の一覧
• 表の一覧
• 分析手法
• 免責事項
• 著作権
• 略語と技術単位
• Lucintelについて
• お問い合わせ

List of Figures

• Figure 1.1: Trends and Forecast for the Global Recombinant Human Follicle Stimulating Hormone Injection Market
• Figure 2.1: Usage of Recombinant Human Follicle Stimulating Hormone Injection Market
• Figure 2.2: Classification of the Global Recombinant Human Follicle Stimulating Hormone Injection Market
• Figure 2.3: Supply Chain of the Global Recombinant Human Follicle Stimulating Hormone Injection Market
• Figure 2.4: Driver and Challenges of the Recombinant Human Follicle Stimulating Hormone Injection Market
• Figure 3.1: Trends of the Global GDP Growth Rate
• Figure 3.2: Trends of the Global Population Growth Rate
• Figure 3.3: Trends of the Global Inflation Rate
• Figure 3.4: Trends of the Global Unemployment Rate
• Figure 3.5: Trends of the Regional GDP Growth Rate
• Figure 3.6: Trends of the Regional Population Growth Rate
• Figure 3.7: Trends of the Regional Inflation Rate
• Figure 3.8: Trends of the Regional Unemployment Rate
• Figure 3.9: Trends of Regional Per Capita Income
• Figure 3.10: Forecast for the Global GDP Growth Rate
• Figure 3.11: Forecast for the Global Population Growth Rate
• Figure 3.12: Forecast for the Global Inflation Rate
• Figure 3.13: Forecast for the Global Unemployment Rate
• Figure 3.14: Forecast for the Regional GDP Growth Rate
• Figure 3.15: Forecast for the Regional Population Growth Rate
• Figure 3.16: Forecast for the Regional Inflation Rate
• Figure 3.17: Forecast for the Regional Unemployment Rate
• Figure 3.18: Forecast for Regional Per Capita Income
• Figure 4.1: Global Recombinant Human Follicle Stimulating Hormone Injection Market by Type in 2019, 2024, and 2031
• Figure 4.2: Trends of the Global Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Type
• Figure 4.3: Forecast for the Global Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Type
• Figure 4.4: Trends and Forecast for 75IU in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Figure 4.5: Trends and Forecast for 150IU in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Figure 4.6: Trends and Forecast for 300IU in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Figure 4.7: Trends and Forecast for Others in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Figure 5.1: Global Recombinant Human Follicle Stimulating Hormone Injection Market by Application in 2019, 2024, and 2031
• Figure 5.2: Trends of the Global Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Application
• Figure 5.3: Forecast for the Global Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Application
• Figure 5.4: Trends and Forecast for Women in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Figure 5.5: Trends and Forecast for Men in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Figure 6.1: Trends of the Global Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Region (2019-2024)
• Figure 6.2: Forecast for the Global Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Region (2025-2031)
• Figure 7.1: Trends and Forecast for the North American Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Figure 7.2: North American Recombinant Human Follicle Stimulating Hormone Injection Market by Type in 2019, 2024, and 2031
• Figure 7.3: Trends of the North American Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Type (2019-2024)
• Figure 7.4: Forecast for the North American Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Type (2025-2031)
• Figure 7.5: North American Recombinant Human Follicle Stimulating Hormone Injection Market by Application in 2019, 2024, and 2031
• Figure 7.6: Trends of the North American Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Application (2019-2024)
• Figure 7.7: Forecast for the North American Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Application (2025-2031)
• Figure 7.8: Trends and Forecast for the United States Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 7.9: Trends and Forecast for the Mexican Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 7.10: Trends and Forecast for the Canadian Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 8.1: Trends and Forecast for the European Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Figure 8.2: European Recombinant Human Follicle Stimulating Hormone Injection Market by Type in 2019, 2024, and 2031
• Figure 8.3: Trends of the European Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Type (2019-2024)
• Figure 8.4: Forecast for the European Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Type (2025-2031)
• Figure 8.5: European Recombinant Human Follicle Stimulating Hormone Injection Market by Application in 2019, 2024, and 2031
• Figure 8.6: Trends of the European Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Application (2019-2024)
• Figure 8.7: Forecast for the European Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Application (2025-2031)
• Figure 8.8: Trends and Forecast for the German Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 8.9: Trends and Forecast for the French Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 8.10: Trends and Forecast for the Spanish Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 8.11: Trends and Forecast for the Italian Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 8.12: Trends and Forecast for the United Kingdom Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 9.1: Trends and Forecast for the APAC Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Figure 9.2: APAC Recombinant Human Follicle Stimulating Hormone Injection Market by Type in 2019, 2024, and 2031
• Figure 9.3: Trends of the APAC Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Type (2019-2024)
• Figure 9.4: Forecast for the APAC Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Type (2025-2031)
• Figure 9.5: APAC Recombinant Human Follicle Stimulating Hormone Injection Market by Application in 2019, 2024, and 2031
• Figure 9.6: Trends of the APAC Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Application (2019-2024)
• Figure 9.7: Forecast for the APAC Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Application (2025-2031)
• Figure 9.8: Trends and Forecast for the Japanese Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 9.9: Trends and Forecast for the Indian Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 9.10: Trends and Forecast for the Chinese Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 9.11: Trends and Forecast for the South Korean Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 9.12: Trends and Forecast for the Indonesian Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 10.1: Trends and Forecast for the ROW Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Figure 10.2: ROW Recombinant Human Follicle Stimulating Hormone Injection Market by Type in 2019, 2024, and 2031
• Figure 10.3: Trends of the ROW Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Type (2019-2024)
• Figure 10.4: Forecast for the ROW Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Type (2025-2031)
• Figure 10.5: ROW Recombinant Human Follicle Stimulating Hormone Injection Market by Application in 2019, 2024, and 2031
• Figure 10.6: Trends of the ROW Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Application (2019-2024)
• Figure 10.7: Forecast for the ROW Recombinant Human Follicle Stimulating Hormone Injection Market ($B) by Application (2025-2031)
• Figure 10.8: Trends and Forecast for the Middle Eastern Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 10.9: Trends and Forecast for the South American Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 10.10: Trends and Forecast for the African Recombinant Human Follicle Stimulating Hormone Injection Market ($B) (2019-2031)
• Figure 11.1: Porter's Five Forces Analysis of the Global Recombinant Human Follicle Stimulating Hormone Injection Market
• Figure 11.2: Market Share (%) of Top Players in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2024)
• Figure 12.1: Growth Opportunities for the Global Recombinant Human Follicle Stimulating Hormone Injection Market by Type
• Figure 12.2: Growth Opportunities for the Global Recombinant Human Follicle Stimulating Hormone Injection Market by Application
• Figure 12.3: Growth Opportunities for the Global Recombinant Human Follicle Stimulating Hormone Injection Market by Region
• Figure 12.4: Emerging Trends in the Global Recombinant Human Follicle Stimulating Hormone Injection Market

List of Tables

• Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Recombinant Human Follicle Stimulating Hormone Injection Market by Type and Application
• Table 1.2: Attractiveness Analysis for the Recombinant Human Follicle Stimulating Hormone Injection Market by Region
• Table 1.3: Global Recombinant Human Follicle Stimulating Hormone Injection Market Parameters and Attributes
• Table 3.1: Trends of the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 3.2: Forecast for the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 4.1: Attractiveness Analysis for the Global Recombinant Human Follicle Stimulating Hormone Injection Market by Type
• Table 4.2: Market Size and CAGR of Various Type in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 4.3: Market Size and CAGR of Various Type in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 4.4: Trends of 75IU in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 4.5: Forecast for 75IU in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 4.6: Trends of 150IU in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 4.7: Forecast for 150IU in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 4.8: Trends of 300IU in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 4.9: Forecast for 300IU in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 4.10: Trends of Others in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 4.11: Forecast for Others in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 5.1: Attractiveness Analysis for the Global Recombinant Human Follicle Stimulating Hormone Injection Market by Application
• Table 5.2: Market Size and CAGR of Various Application in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 5.3: Market Size and CAGR of Various Application in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 5.4: Trends of Women in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 5.5: Forecast for Women in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 5.6: Trends of Men in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 5.7: Forecast for Men in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 6.1: Market Size and CAGR of Various Regions in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 6.2: Market Size and CAGR of Various Regions in the Global Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 7.1: Trends of the North American Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 7.2: Forecast for the North American Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 7.3: Market Size and CAGR of Various Type in the North American Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 7.4: Market Size and CAGR of Various Type in the North American Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 7.5: Market Size and CAGR of Various Application in the North American Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 7.6: Market Size and CAGR of Various Application in the North American Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 7.7: Trends and Forecast for the United States Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 7.8: Trends and Forecast for the Mexican Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 7.9: Trends and Forecast for the Canadian Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 8.1: Trends of the European Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 8.2: Forecast for the European Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 8.3: Market Size and CAGR of Various Type in the European Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 8.4: Market Size and CAGR of Various Type in the European Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 8.5: Market Size and CAGR of Various Application in the European Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 8.6: Market Size and CAGR of Various Application in the European Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 8.7: Trends and Forecast for the German Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 8.8: Trends and Forecast for the French Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 8.9: Trends and Forecast for the Spanish Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 8.10: Trends and Forecast for the Italian Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 8.11: Trends and Forecast for the United Kingdom Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 9.1: Trends of the APAC Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 9.2: Forecast for the APAC Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 9.3: Market Size and CAGR of Various Type in the APAC Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 9.4: Market Size and CAGR of Various Type in the APAC Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 9.5: Market Size and CAGR of Various Application in the APAC Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 9.6: Market Size and CAGR of Various Application in the APAC Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 9.7: Trends and Forecast for the Japanese Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 9.8: Trends and Forecast for the Indian Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 9.9: Trends and Forecast for the Chinese Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 9.10: Trends and Forecast for the South Korean Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 9.11: Trends and Forecast for the Indonesian Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 10.1: Trends of the ROW Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 10.2: Forecast for the ROW Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 10.3: Market Size and CAGR of Various Type in the ROW Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 10.4: Market Size and CAGR of Various Type in the ROW Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 10.5: Market Size and CAGR of Various Application in the ROW Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2024)
• Table 10.6: Market Size and CAGR of Various Application in the ROW Recombinant Human Follicle Stimulating Hormone Injection Market (2025-2031)
• Table 10.7: Trends and Forecast for the Middle Eastern Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 10.8: Trends and Forecast for the South American Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 10.9: Trends and Forecast for the African Recombinant Human Follicle Stimulating Hormone Injection Market (2019-2031)
• Table 11.1: Product Mapping of Recombinant Human Follicle Stimulating Hormone Injection Suppliers Based on Segments
• Table 11.2: Operational Integration of Recombinant Human Follicle Stimulating Hormone Injection Manufacturers
• Table 11.3: Rankings of Suppliers Based on Recombinant Human Follicle Stimulating Hormone Injection Revenue
• Table 12.1: New Product Launches by Major Recombinant Human Follicle Stimulating Hormone Injection Producers (2019-2024)
• Table 12.2: Certification Acquired by Major Competitor in the Global Recombinant Human Follicle Stimulating Hormone Injection Market

The future of the global recombinant human follicle stimulating hormone injection market looks promising with opportunities in the women and men markets. The global recombinant human follicle stimulating hormone injection market is expected to grow with a CAGR of 5.3% from 2025 to 2031. The major drivers for this market are the increasing prevalence of infertility and the growing availability of biosimilars.

• Lucintel forecasts that, within the type category, 150IU is expected to witness the highest growth over the forecast period.
• Within the application category, women are expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Recombinant Human Follicle Stimulating Hormone Injection Market

The recombinant human follicle stimulating hormone injection industry is going through drastic changes with the changing medical practices, technology upgrades, and patient requirements. Some of the prominent trends are defining its future course.

• Personalized Fertility Treatments: Clinicians are increasingly individualizing fertility protocols with diagnostics and medical history in an effort to maximize success rates while reducing side effects by optimizing FSH dosing and treatment length.
• Transition to Recombinant FSH: Recombinant FSH is gaining popularity over urinary-based products as a result of its purity, consistency, and safety. Consistent performance has enhanced clinician and patient acceptance, resulting in increased market share.
• Emergence of Biosimilars: As original FSH patents expire, biosimilar products are appearing. They are as effective and safe, but at a lower price, expanding access to treatment and promoting price competition.
• Better Drug Delivery: Technologies such as prefilled pens and long-acting FSH formulations increase convenience, minimize the pain of injections, and enhance adherence to therapy by patients.
• Expanded Therapeutic Use: Investigation is underway into recombinant FSH for other endocrine and reproductive conditions other than infertility, with a possible broadened clinical application and market opportunity.

These trends are all coming together to redefine the recombinant human follicle stimulating hormone injection market as it fuels innovation, facilitates better access to treatments, and opens up broader applications of these life-saving therapies. The emphasis on personalized treatment, cutting-edge formulations, and affordable options is likely to keep defining the market trends in the future as well.

Recent Developments in the Recombinant Human Follicle Stimulating Hormone Injection Market

The recombinant human follicle stimulating hormone injection market is dominated by continuous innovations to enhance efficacy, safety, and convenience for patients. Such developments cut across different dimensions, ranging from drug formulation to delivery to therapeutic use.

• Novel Formulations: Pharmaceutical firms are continually innovating to create better formulations of recombinant FSH. This involves the creation of extended-release forms that decrease the number of injections, alongside more stable formulations with lower excipient content to prevent possible side effects. For example, certain firms are researching sustained-release forms that would deliver a more physiological pattern of hormone release over an extended time, which would result in improved treatment outcomes.
• Growing Availability of Biosimilars: With the patent expiration of many of the pioneering recombinant FSH products, biosimilar versions are gaining greater availability across different markets. The biosimilars are tested extensively to prove similar efficacy and safety compared to the respective reference products, providing affordable treatment to patients. The emergence of biosimilars is promoting more competition in the market, which can reduce prices and enhance access to necessary fertility treatments.
• Process Improvements in Manufacturing: Ongoing improvements in recombinant DNA technology and cell culture processes are resulting in more cost-effective and efficient manufacturing processes for recombinant FSH. These process improvements provide a stable and consistent supply of high-quality products to address the increasing global demand. Improved production processes can also help lower the overall cost of treatment, making it more available to a larger patient population.
• Emphasis on Greater Patient Convenience: Drug delivery systems are transforming to enhance patient convenience. Prefilled pens with easy-to-use designs, thinner needles, and precise dosing mechanisms are increasingly popular. These features make self-administration easier, minimize anxiety associated with injections, and enhance compliance with treatment regimens. The focus on convenience for the patient is aimed at making fertility treatments less cumbersome and more convenient for patients undergoing treatment.
• Investigation of Novel Therapeutic Uses: Although applied mainly in assisted reproductive technologies, research is considering recombinant FSH's possibility for the treatment of other conditions. These involve testing its use in controlling certain types of hormonal deficiencies and reproductive health outside of infertility. Even if these uses are still under exploration, positive results could very much increase the therapeutic application of recombinant FSH.

These major advances are cumulatively affecting the recombinant human follicle stimulating hormone injection market by advancing treatment modalities, facilitating access to patients, and possibly broadening the clinical use of these critical drugs. The continuing emphasis on innovation in formulation, manufacturing, delivery, and therapeutic use reflects a dynamic and changing market environment.

Strategic Growth Opportunities in the Recombinant Human Follicle Stimulating Hormone Injection Market

The recombinant human follicle stimulating hormone injection market offers a number of strategic opportunities for growth across its major applications, mainly in the context of assisted reproductive technologies as well as treatments for infertility.

• Increasing Access to Infertility Care in Developing Countries: Developing countries have an enormous unmet need for infertility treatments based on limited access, unaffordability, and social stigma. Strategic action including expanding awareness, adding more fertility clinics, and providing affordable recombinant FSH options can drive significant growth in these markets. Collaboration with local healthcare providers and governments can help penetrate these markets and address the regional unique needs.
• Growing Use in Reproductive Technologies (ART) Advances: The ongoing developments in ART technologies, including preimplantation genetic testing (PGT) and oocyte cryopreservation, are fueling the need for quality gonadotropins such as recombinant FSH. As success rates of these advanced technologies continue to rise, use in recombinant FSH for controlled ovarian stimulation is anticipated to grow. Embracing development of customized FSH protocols for these special ART procedures is a high-growth opportunity.
• Creating Patient-Specific Treatment Solutions: Focusing treatment strategies on patient-specific profiles, such as age, ovarian reserve, and prior ART success, can maximize success rates and patient satisfaction. Creating diagnostic products and treatment protocols that allow for personalized recombinant FSH dosing and administration regimens can create a competitive edge. Providing a range of support services and educational materials can further increase the patient experience and fuel market growth.
• Utilizing Biosimilars to Improve Affordability and Access: The launch of biosimilar recombinant FSH products presents a possibility of increasing the accessibility of treatments by offering more cost-effective options over reference brands. Strategic collaborations on the production and marketing of biosimilars in price-sensitive markets can gain a greater share of the patient base. Educating patients on the similar efficacy and safety of biosimilars through comprehensive clinical evidence and patient education can encourage take-up.
• Investigating Combination Therapies and New Treatment Regimens: Studies on synergistic actions of recombinant FSH with other fertility medications or new treatment regimens can result in better outcomes and new market potential. Studying the best timing and dose of recombinant FSH in combination with other gonadotropins or add-back therapies can maximize follicular growth and pregnancy rates. Partnerships with research centers and opinion leaders can support the establishment and validation of these new strategies.

These strategic areas for growth, aimed at increasing geographical extent, maximizing utilization in cutting-edge ART, individualizing treatment, taking advantage of biosimilars, and investigating new therapeutic methods, offer great potential for fueling the growth of the recombinant human follicle stimulating hormone injection market.

Recombinant Human Follicle Stimulating Hormone Injection Market Driver and Challenges

The recombinant human follicle stimulating hormone injection market is influenced by a complex interplay of drivers and challenges stemming from technological, economic, and regulatory factors. Understanding these dynamics is crucial for stakeholders navigating this evolving landscape.

The factors responsible for driving the recombinant human follicle stimulating hormone injection market include:

1. Increasing Global Infertility Rates: The growing rate of infertility globally, due to lifestyle factors, environmental disruptors, and delayed childbearing, is a major impetus for the use of fertility treatments, including recombinant FSH injections. As couples experience more trouble conceiving, the demand for successful assisted reproductive technologies dependent upon FSH stimulation persists.

2. Development in Assisted Reproductive Technologies (ART): Continuous development and rising success rates in ART treatments such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) are considerably driving the demand for recombinant FSH. The technologies significantly depend on controlled ovarian stimulation by FSH to harvest multiple mature eggs, and hence it is an integral part of contemporary infertility therapy.

3. Increasing Awareness and Acceptance of Fertility Treatments: Greater awareness regarding infertility as a medical condition and destigmatization of fertility treatments are motivating more couples and individuals towards seeking medical help. This change in societal attitude is widening the patient base for recombinant FSH injections and other fertility treatments.

4. Recombinant Technology Development and Availability: The availability of recombinant DNA technology has facilitated mass production of high-purity and reproducible FSH, which was not possible with the previous urinary-derived products. The consistency and safety profile of the recombinant FSH have established it as the first choice among clinicians and patients, fueling market expansion.

5. Growing Healthcare Spending and Government Support: Increased healthcare expenditure across the world and supportive government policies for enhancing access to reproductive health care facilities in certain areas are fueling the recombinant FSH market. Public funding and reimbursement regulations of fertility therapies have the ability to affect the affordability and access to such treatments appreciably.

Challenges in the recombinant human follicle stimulating hormone injection market are:

1. Exorbitant Treatment Cost: The expense of recombinant FSH injection and related ART treatments can prove to be a major hindrance for most couples, especially in developing nations or areas with poor insurance coverage. Affordability continues to be the biggest challenge that can limit market growth and patient access.

2. Strict Regulatory Requirements: Recombinant FSH products are under strict regulatory oversight to ensure safety and efficacy during development, manufacturing, and commercialization. Complying with these sophisticated and frequently time-consuming approval procedures can prove burdensome for manufacturers and might cause delays in the release of new products or biosimilars.

3. Possible Side Effects and Risks: Though in general good tolerability, recombinant FSH treatment may be related to possible side effects like ovarian hyperstimulation syndrome (OHSS) and multiple pregnancies. These risks can shape patient and physician choices and need good monitoring and management throughout treatment.

Overall, the market for recombinant human follicle stimulating hormone injections is fueled mainly by rising rates of infertility, technological advancements in ART, heightened awareness of treatment, and advantages offered by recombinant technology. Nevertheless, issues involving treatment cost, regulatory hurdles, and side effects must be met for proper access to prevail and ensure long-term market growth. Tackling these issues through innovative pricing, efficient regulatory processes for biosimilars, and enhanced patient education and safety measures will be vital to the future of the market.

List of Recombinant Human Follicle Stimulating Hormone Injection Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leveraging integration opportunities across the value chain. With these strategies, recombinant human follicle stimulating hormone injection companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the recombinant human follicle stimulating hormone injection companies profiled in this report include:

• Merck
• Organon
• Gedeon Richter
• Ferring
• Changchun High-Tech

Recombinant Human Follicle Stimulating Hormone Injection Market by Segment

The study includes a forecast for the global recombinant human follicle stimulating hormone injection market by type, application, and region.

Recombinant Human Follicle Stimulating Hormone Injection Market by Type [Value from 2019 to 2031]:

• 75IU
• 150IU
• 300IU
• Others

Recombinant Human Follicle Stimulating Hormone Injection Market by Application [Value from 2019 to 2031]:

• Women
• Men

Recombinant Human Follicle Stimulating Hormone Injection Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Recombinant Human Follicle Stimulating Hormone Injection Market

Current trends in the recombinant human follicle stimulating hormone injection market are a world trend towards more sophisticated treatments for infertility. Recombinant FSH provides high purity and batch-to-batch consistency, better than urinary-derived products. The growing incidence of infertility, combined with increased use of Assisted Reproductive Technologies, is driving market growth in major regions. Regulatory environments and the launch of biosimilars are also influencing market dynamics. This background provides the context for more detailed exploration of individual advances within the United States, China, Germany, India, and Japan.

• United States: The US market for recombinant human follicle stimulating hormone injections is supported by strong adoption rates of Assisted Reproductive Technologies and an established healthcare infrastructure. Recent advances have included increased focus on personalized medicine, in which treatment protocols are customized to address specific patient needs in order to maximize success rates. In addition, there is greater awareness and acceptance of fertility treatments that drive market growth. Strong regulatory support and high disposable incomes also make these treatments accessible and affordable.
• China: The Chinese market has witnessed an increasing acceptance of macromolecular bioengineered drugs such as recombinant human olitorin in Assisted Reproductive Technologies and sex hormone therapies, in place of small-molecule chemicals because of their purity and stability. Higher rates of infertility caused by environmental contamination and changing lifestyle, coupled with an increasing mean childbearing age and eased family planning policy, are fueling demand. While traditionally controlled by a handful of companies, the market is set to witness the introduction of more generic recombinant FSH offerings in the near future, which can possibly boost availability.
• Germany: Recent news in Germany includes the launch and growing use of biosimilar versions of recombinant human follicle stimulating hormone. These biosimilars are similar in efficacy and safety to reference products such as Goal-f, but potentially at a lower price, which could enhance patient access. Research continues to improve production processes and the long-term stability of these preparations. The highly developed healthcare sector and the high level of awareness about infertility treatment are responsible for a strong market for original and biosimilar recombinant FSH products.
• India: The Indian market is experiencing growing access to recombinant human follicle stimulating hormone injections, led by rising numbers of fertility clinics and increasing awareness about infertility treatment. Market development and reduced treatment expenses are being driven by regulatory approvals for recombinant FSH products produced domestically. Clinical tests are being conducted to determine bioequivalence with the well-established brands, adding further impetus to the use of local alternatives. The emphasis is on making cost-effective and affordable choices available for the growing number of couples searching for solutions to infertility.
• Japan: In Japan, recombinant human follicle stimulating hormone injections have received approval for use in ovulation induction in infertile women, moving beyond their original applications in the treatment of male infertility. Prefilled pen formulations are designed to make the medication more convenient and accessible for patients. Although the market is driven by a traditionally conservative attitude toward new therapies, growing demand for infertility treatments and access to user-friendly delivery systems are driving incremental market growth.

Features of the Global Recombinant Human Follicle Stimulating Hormone Injection Market

• Market Size Estimates: Recombinant human follicle stimulating hormone injection market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Recombinant human follicle stimulating hormone injection market size by type, application, and region in terms of value ($B).
• Regional Analysis: Recombinant human follicle stimulating hormone injection market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the recombinant human follicle stimulating hormone injection market.
• Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the recombinant human follicle stimulating hormone injection market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the recombinant human follicle stimulating hormone injection market by type (75IU, 150IU, 300IU, and others), application (women and men), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Recombinant Human Follicle Stimulating Hormone Injection Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 75IU: Trends and Forecast (2019-2031)
• 4.4 150IU: Trends and Forecast (2019-2031)
• 4.5 300IU: Trends and Forecast (2019-2031)
• 4.6 Others: Trends and Forecast (2019-2031)

5. Global Recombinant Human Follicle Stimulating Hormone Injection Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Women: Trends and Forecast (2019-2031)
• 5.4 Men: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Recombinant Human Follicle Stimulating Hormone Injection Market by Region

7. North American Recombinant Human Follicle Stimulating Hormone Injection Market

• 7.1 Overview
• 7.2 North American Recombinant Human Follicle Stimulating Hormone Injection Market by Type
• 7.3 North American Recombinant Human Follicle Stimulating Hormone Injection Market by Application
• 7.4 United States Recombinant Human Follicle Stimulating Hormone Injection Market
• 7.5 Mexican Recombinant Human Follicle Stimulating Hormone Injection Market
• 7.6 Canadian Recombinant Human Follicle Stimulating Hormone Injection Market

8. European Recombinant Human Follicle Stimulating Hormone Injection Market

• 8.1 Overview
• 8.2 European Recombinant Human Follicle Stimulating Hormone Injection Market by Type
• 8.3 European Recombinant Human Follicle Stimulating Hormone Injection Market by Application
• 8.4 German Recombinant Human Follicle Stimulating Hormone Injection Market
• 8.5 French Recombinant Human Follicle Stimulating Hormone Injection Market
• 8.6 Spanish Recombinant Human Follicle Stimulating Hormone Injection Market
• 8.7 Italian Recombinant Human Follicle Stimulating Hormone Injection Market
• 8.8 United Kingdom Recombinant Human Follicle Stimulating Hormone Injection Market

9. APAC Recombinant Human Follicle Stimulating Hormone Injection Market

• 9.1 Overview
• 9.2 APAC Recombinant Human Follicle Stimulating Hormone Injection Market by Type
• 9.3 APAC Recombinant Human Follicle Stimulating Hormone Injection Market by Application
• 9.4 Japanese Recombinant Human Follicle Stimulating Hormone Injection Market
• 9.5 Indian Recombinant Human Follicle Stimulating Hormone Injection Market
• 9.6 Chinese Recombinant Human Follicle Stimulating Hormone Injection Market
• 9.7 South Korean Recombinant Human Follicle Stimulating Hormone Injection Market
• 9.8 Indonesian Recombinant Human Follicle Stimulating Hormone Injection Market

10. ROW Recombinant Human Follicle Stimulating Hormone Injection Market

• 10.1 Overview
• 10.2 ROW Recombinant Human Follicle Stimulating Hormone Injection Market by Type
• 10.3 ROW Recombinant Human Follicle Stimulating Hormone Injection Market by Application
• 10.4 Middle Eastern Recombinant Human Follicle Stimulating Hormone Injection Market
• 10.5 South American Recombinant Human Follicle Stimulating Hormone Injection Market
• 10.6 African Recombinant Human Follicle Stimulating Hormone Injection Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Recombinant Human Follicle Stimulating Hormone Injection Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Merck
  • Company Overview
  • Recombinant Human Follicle Stimulating Hormone Injection Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Organon
  • Company Overview
  • Recombinant Human Follicle Stimulating Hormone Injection Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Gedeon Richter
  • Company Overview
  • Recombinant Human Follicle Stimulating Hormone Injection Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Ferring
  • Company Overview
  • Recombinant Human Follicle Stimulating Hormone Injection Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Changchun High-Tech
  • Company Overview
  • Recombinant Human Follicle Stimulating Hormone Injection Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us